Headache Medicine and Women's Health Series: Menstrual Migraine
Release Date: 01/06/2026
A Discussion with Dr. Alison Christy: 2026 Ted Burns Humanism in Neurology Award Winner
Neurology Minute
Dr. Stacey Clardy talks with Dr. Alison Christy, the recipient of the 2026 Ted Burns Humanism in Neurology Award, about her inspiring career, innovative approaches to neurology education, and how she fosters compassion and creativity in medicine.
info_outline
Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021
Neurology Minute
Dr. Tesha Monteith talks with Ayesha Sohail about her abstract titled "Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021: An Analysis of Epidemiology, Trends, and Socioeconomic Disparities." Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 3
Neurology Minute
In the final episode of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the study results and their implications for improving clinical practice. Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss how this technology was developed and how it has evolved. Read more about this abstract on the .
info_outline
2026 AAN President's Award Recipient - Dr. Walter J. Koroshetz
Neurology Minute
Dr. Greg Cooper talks with Dr. Walter J. Koroshetz about his advice for early neurologists. Read more about the .
info_outline
A Path to Preventing Cognitive Impairment Due to Alzheimer's Disease
Neurology Minute
Dr. Greg Cooper and Dr. Eric Reiman discuss emerging antibody therapies for preclinical Alzheimer's disease and the clinical, regulatory, and equity considerations shaping prevention trials and future care. Show citation: Reiman EM, Alexander RC, Langbaum JB, et al. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. Lancet Neurol. 2026;25(3):268-278. doi:
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 1
Neurology Minute
In the first part of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the background and evolving terminology around circulating tumor DNA, cell‑free DNA and CSF‑based testing in neurology. Read more about this abstract on the .
info_outline
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the clinical trial design, including the objectives and methods. Read more about this abstract on the .
info_outline
April 6, 2026 Capitol Hill Report: Proposed Budget Cuts, New Bills
Neurology Minute
In this episode, Dr. Andy Southerland reviews the Capitol Hill Report from April 6th, focusing on news related to appropriations and several new bills. Stay updated with what’s happening on the hill by visiting . Learn how you can get involved with .
info_outline
History of Letters to the Editor
Neurology Minute
As we celebrate the 75th anniversary of Neurology®, Drs. Jeff Ratliff, Steven Galetta, and Robert Griggs discuss the history and evolution of the Letters to the Editor section. Join the conversation by visiting the .
info_outlineDr. Tesha Monteith discusses menstrual migraine and treatment options.
Show transcript:
Dr. Tesha Monteith:
This is Tesha Monteith with the Neurology Minute. Welcome back to our series on headache medicine and women's health. I'm continuing our discussion on menstrual migraine, and I want to focus on treatment. We talked about increasing the yield of diagnosis for menstrual migraine, but what are the best ways to treat our patients? I think there are two broad categories we can think about:
We can think about non-hormonal methods or hormonal methods. The non-hormonal methods include a combination of abortive therapies, as well as preventative therapies that can be used for a mini prophylaxis, as well as when patients have a higher burden of overall migraine, considering the general highly effective preventive therapies.
Common mini prophylaxis include triptans such as Frovatriptan, Naratriptan, and Zolmitriptan when used twice per day. Nonsteroidal anti-inflammatories can be used for five to seven days around menses, such as naproxen, 550 milligrams twice per day. Magnesium, 360 milligrams daily or higher, can also be started mid-cycle, so day 15, towards menstruation.
Although considered off-label, gepants, ubrogepant, as well as rimegepant, can also be used during the susceptible window.
This is Tesha Monteith. Thank you for listening to the Neurology Minute.